Masimo (NASDAQ: MASI) announced today that O3® Regional Oximetry has received FDA clearance for use on neonatal indication and infant patients (<10 kg). O3...
Masimo (NASDAQ: MASI) announced today that O3® Regional Oximetry has received FDA clearance for use on neonatal indication and infant patients (<10 kg). O3...
